Literature DB >> 26134233

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.

Gouji Toyokawa1, Eiko Inamasu, Shinichiro Shimamatsu, Tsukihisa Yoshida, Kaname Nosaki, Fumihiko Hirai, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26134233     DOI： 10.1097/JTO.0000000000000509

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  30 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Jann N Sarkaria; William F Elmquist
Journal:  Pharmacol Res       Date:  2017-06-17       Impact factor: 7.658

Review 3.  Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.

Authors:  Xiaomin Niu; Jody C Chuang; Gerald J Berry; Heather A Wakelee
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

4.  Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors.

Authors:  Elena Poddubskaya; Alexey Bondarenko; Alexander Boroda; Evgenia Zotova; Alex Glusker; Svetlana Sletina; Luidmila Makovskaia; Philipp Kopylov; Marina Sekacheva; Alexey Moisseev; Madina Baranova
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

Review 5.  Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Authors:  Biagio Ricciuti; Andrea De Giglio; Carmen Mecca; Cataldo Arcuri; Sabrina Marini; Giulio Metro; Sara Baglivo; Angelo Sidoni; Guido Bellezza; Lucio Crinò; Rita Chiari
Journal:  Med Oncol       Date:  2018-04-17       Impact factor: 3.064

6.  A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors:  Sawsan Rashdan; David E Gerber
Journal:  Transl Cancer Res       Date:  2017-02       Impact factor: 1.241

Review 7.  Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.

Authors:  M Drizou; E A Kotteas; N Syrigos
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

Review 8.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.

Authors:  Alison M Schram; Matthew T Chang; Philip Jonsson; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

Review 9.  Personalized therapy for lung cancer: striking a moving target.

Authors:  Suchita Pakkala; Suresh S Ramalingam
Journal:  JCI Insight       Date:  2018-08-09

10.  Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.

Authors:  Leora Horn; Jennifer G Whisenant; Heather Wakelee; Karen L Reckamp; Huan Qiao; Ticiana A Leal; Liping Du; Jennifer Hernandez; Vincent Huang; George R Blumenschein; Saiama N Waqar; Sandip P Patel; Jorge Nieva; Geoffrey R Oxnard; Rachel E Sanborn; Tristan Shaffer; Kavita Garg; Allison Holzhausen; Kimberly Harrow; Chris Liang; Lee P Lim; Mark Li; Christine M Lovly
Journal:  J Thorac Oncol       Date:  2019-08-22       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.